LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis.
HCC
LiMAx®
enzymatic liver function test
hepatocellular carcinoma
radioembolization
selective internal radiotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Sep 2022
21 Sep 2022
Historique:
received:
29
08
2022
revised:
16
09
2022
accepted:
17
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Radioembolization (RE) has recently demonstrated a non-inferior survival outcome compared to systemic therapy for advanced hepatocellular carcinoma (HCC). Therefore, current guidelines recommend RE for patients with advanced HCC and preserved liver function who are unsuitable for transarterial chemoembolization (TACE) or systemic therapy. However, despite the excellent safety profile of RE, post-therapeutic hepatic decompensation remains a serious complication that is difficult to predicted by standard laboratory liver function parameters or imaging modalities. LiMAx In total, 50 patients with HCC with or without liver cirrhosis and not amenable to TACE or systemic treatments were included in the study. For patients prospectively enrolled in our study, LiMAx We observed a strong association between baseline LiMAx Patients with lower LiMAx
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Radioembolization (RE) has recently demonstrated a non-inferior survival outcome compared to systemic therapy for advanced hepatocellular carcinoma (HCC). Therefore, current guidelines recommend RE for patients with advanced HCC and preserved liver function who are unsuitable for transarterial chemoembolization (TACE) or systemic therapy. However, despite the excellent safety profile of RE, post-therapeutic hepatic decompensation remains a serious complication that is difficult to predicted by standard laboratory liver function parameters or imaging modalities. LiMAx
PATIENTS AND METHODS
METHODS
In total, 50 patients with HCC with or without liver cirrhosis and not amenable to TACE or systemic treatments were included in the study. For patients prospectively enrolled in our study, LiMAx
RESULTS
RESULTS
We observed a strong association between baseline LiMAx
CONCLUSION
CONCLUSIONS
Patients with lower LiMAx
Identifiants
pubmed: 36230506
pii: cancers14194584
doi: 10.3390/cancers14194584
pmc: PMC9558955
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Humedics (Germany)
ID : 108-21280
Références
J Hepatol. 2019 Dec;71(6):1164-1174
pubmed: 31421157
J Clin Oncol. 2018 Jul 1;36(19):1913-1921
pubmed: 29498924
Sci Rep. 2018 Jul 3;8(1):9997
pubmed: 29968763
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Hepatology. 2021 Jan;73 Suppl 1:4-13
pubmed: 32319693
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Liver Transpl. 2010 Feb;16(2):172-80
pubmed: 20104485
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
Expert Rev Gastroenterol Hepatol. 2022 Apr;16(4):333-339
pubmed: 35403533
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
HPB (Oxford). 2010 Mar;12(2):139-46
pubmed: 20495659
J Hepatol. 2022 Apr;76(4):862-873
pubmed: 34902530
Cancers (Basel). 2021 Oct 29;13(21):
pubmed: 34771591
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255
pubmed: 30285213
Expert Rev Gastroenterol Hepatol. 2021 Nov;15(11):1245-1251
pubmed: 34431725
Visc Med. 2021 Mar;37(2):94-101
pubmed: 33977098
J Dig Dis. 2014 Aug;15(8):444-50
pubmed: 24828952
J Nucl Med. 2020 Dec;61(12):1736-1742
pubmed: 32358087
Cardiovasc Intervent Radiol. 2019 Dec;42(12):1702-1708
pubmed: 31535181
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Hepatobiliary Surg Nutr. 2022 Aug;11(4):592-596
pubmed: 36016731
Ann Oncol. 2021 Jun;32(6):801-805
pubmed: 33716105
Dig Dis. 2022 Feb 22;:
pubmed: 35193135
Liver Cancer. 2019 Nov;8(6):491-504
pubmed: 31799206
Gastroenterology. 2011 Feb;140(2):497-507.e2
pubmed: 21044630
Sci Rep. 2021 Jul 5;11(1):13834
pubmed: 34226640
Int J Surg. 2019 Nov;71:56-65
pubmed: 31494333
Clin Gastroenterol Hepatol. 2013 Oct;11(10):1358-1365.e1
pubmed: 23644386
Trials. 2014 Dec 03;15:474
pubmed: 25472660
Dig Dis Sci. 2021 Jul;66(7):2452-2460
pubmed: 32816218
HPB (Oxford). 2014 Mar;16(3):243-9
pubmed: 23530966
Hepatology. 2017 Sep;66(3):969-982
pubmed: 28407278
Ann Surg. 2009 Jul;250(1):119-25
pubmed: 19561474
Cancers (Basel). 2021 Jul 28;13(15):
pubmed: 34359695